Frank Elbert Anderson, Iii

Title: Frank Elbert Anderson, III: Innovator in E-Selectin Antagonist Compounds

Introduction

Frank Elbert Anderson, III is a notable inventor based in Gaithersburg, MD (US). He holds a total of 10 patents, showcasing his significant contributions to the field of medical research and treatment. His work primarily focuses on E-selectin antagonist compounds, which have important implications for cancer treatment.

Latest Patents

Anderson's latest patents include methods and compositions using E-selectin antagonists for the treatment and prevention of diseases. These methods aim to inhibit the binding of E-selectin to its ligand, which is crucial in treating various cancers. The patents describe E-selectin antagonists such as glycomimetic compounds, antibodies, aptamers, and peptides. These compounds are designed to prevent metastasis, inhibit cancer cell infiltration into bone marrow, and reduce adhesion of cancer cells to endothelial cells, thereby inhibiting thrombus formation.

Career Highlights

Throughout his career, Anderson has worked with prominent companies in the biotechnology sector, including Glycomimetics, Inc. and Martek Biosciences Corporation. His innovative research has led to advancements in therapeutic methods that address critical health challenges.

Collaborations

Anderson has collaborated with esteemed colleagues in his field, including John L. Magnani and Arun K. Sarkar. These partnerships have contributed to the development of groundbreaking treatments and methodologies.

Conclusion

Frank Elbert Anderson, III is a distinguished inventor whose work on E-selectin antagonists has the potential to transform cancer treatment. His extensive patent portfolio and collaborations highlight his commitment to advancing medical science.